1. Home
  2. DUO vs GNPX Comparison

DUO vs GNPX Comparison

Compare DUO & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DUO

Fangdd Network Group Ltd.

HOLD

Current Price

$1.95

Market Cap

7.5M

Sector

Finance

ML Signal

HOLD

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$2.73

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DUO
GNPX
Founded
2011
2009
Country
China
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
6.5M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
DUO
GNPX
Price
$1.95
$2.73
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
109.7K
322.7K
Earning Date
11-19-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$56,189,313.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
48.30
N/A
52 Week Low
$1.24
$2.61
52 Week High
$14.40
$63.00

Technical Indicators

Market Signals
Indicator
DUO
GNPX
Relative Strength Index (RSI) 48.14 41.21
Support Level $1.86 $3.15
Resistance Level $2.44 $3.68
Average True Range (ATR) 0.15 0.28
MACD 0.06 -0.01
Stochastic Oscillator 37.18 18.80

Price Performance

Historical Comparison
DUO
GNPX

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: